allogeneic anti-CD123 DAR T-cell therapy (Sorrento Therapeutics)

N/A

Report date: 2025/01/26 18:16:18

Base Information

Drug Nameallogeneic anti-CD123 DAR T-cell therapy (Sorrento Therapeutics)

Drug Alias Nameallogeneic anti-CD123 CAR T-cell therapy (Sorrento Therapeutics)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionInterleukin-3 receptor subunit alpha modulators

TargetsInterleukin-3 receptor subunit alpha

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSorrento Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesSorrento Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A